Human monkeypox virus infection in an immunocompromised man: trial with tecovirimat

Hernandez, Loren; Jadoo, Arvin; Kirsner, Robert S.

doi:10.1016/s0140-6736(22)01528-8

Cited by 27 publications

(33 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In non-human primate models of monkeypox disease, tecovirimat improves survival, 123 and case studies in humans show anecdotal improvement of symptoms and viral clearance. 24 , 130 , 131 The medication is well tolerated with the most commonly reported side-effects being headache, nausea, and abdominal pain, although the adverse effects profile was similar to placebo in a trial involving 360 healthy volunteers. 123 Tecovirimat appears effective in vitro against the monkeypox virus lineage responsible for the 2022 outbreak; 132 , 133 however, cases of genotypic and phenotypic resistance have been reported and alternative drugs should be considered in patients who do not respond to tecovirimat (ie, continue to develop lesions or complications after a 14-day course).…”

Section: Treatmentmentioning

confidence: 99%

Monkeypox

Mitjà¹,

Ogoina²,

Titanji³

et al. 2023

The Lancet

323

276

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Monkeypox

Mitjà¹,

Ogoina²,

Titanji³

et al. 2023

The Lancet

323

276

View full text Add to dashboard Cite

“…In 2022, an adult immunocompromised man with MPXV infection in the USA received a two-week course of Tecovirimat twice a day. He did not report any significant adverse effects, and the skin lesions healed quickly [ 46 ]. Brincidofovir is an antiviral drug that inhibits nucleotide analog DNA polymerase in orthopoxviruses and also inhibits the replication of MPXV [ 47 ].…”

Section: Treatmentmentioning

confidence: 99%

Diagnosis, treatment, and prevention of monkeypox in children: an experts’ consensus statement

et al. 2022

View full text Add to dashboard Cite

Monkeypox is a zoonotic disease. Since the first human monkeypox case was detected in 1970, it has been prevalent in some countries in central and western Africa. Since May 2022, monkeypox cases have been reported in more than 96 non-endemic countries and regions worldwide. As of September 14, 2022, there have been more than 58,200 human monkeypox cases, and there is community transmission. The cessation of smallpox vaccination in 1980, which had some cross-protection with monkeypox, resulted in a general lack of immunity to monkeypox, which caused global concern and vigilance. As of September 14, 2022, there are four monkeypox cases in China, including three in Taiwan province and one in Hong Kong city. Previous foreign studies have shown that children are vulnerable to monkeypox and are also at high risk for severe disease or complications. In order to improve pediatricians’ understanding of monkeypox and achieve early detection, early diagnosis, early treatment, and early disposal, we have organized national authoritative experts in pediatric infection, respiratory, dermatology, critical care medicine, infectious diseases, and public health and others to formulate this expert consensus, on the basis of the latest “ Clinical management and infection prevention and control for monkeypox ” released by The World Health Organization, the “ guidelines for diagnosis and treatment of monkeypox (version 2022) ” issued by National Health Commission of the People’s Republic of China and other relevant documents. During the development of this consensus, multidisciplinary experts have repeatedly demonstrated the etiology, epidemiology, transmission, clinical manifestations, laboratory examinations, diagnosis, differential diagnosis, treatment, discharge criteria, prevention, disposal process, and key points of prevention and control of suspected and confirmed cases.

show abstract

“… M= 38 years Not mentioned N/A MSM: 83.5% Sexual Vusirikala et al [ 24 ] Cross-sectional UK 45 Male M= 40 years 26% [60%] Past history MSM: 44 [98%] Sexual Lima et al [ 25 ] Case report Brazil 1 Male 41 Not available Not mentioned MSM Sexual Brites et al [ 26 ] Case report Brazil 2 Male 37 31 50% Not mentioned MSM Not indicated Menezes et al [ 27 ] Case report Brazil 1 Male 41 100% Not mentioned MSM Sexual Karan A, et al [ 28 ] Case report USA 1 Male 20s 0% Past history Syphilis MSM close, nonsexual contact with numerous unknown persons at a crowded outdoor event. Hernandez LE, et al [ 29 ] Case report USA 1 Male 37 100% Past history Syphilis Not mentioned Unknown Philpott D, et al [ 30 ] Case series USA 1194 99% males M=35 years Among 334 persons with available HIV data, 136 [41%] had HIV infection Not mentioned Not clear Among 358 [30%] men with information on sexual encounters, 337 [94%] reported sex or close intimate ...…”

Section: Resultsmentioning

confidence: 99%

“…All studies included in this review, except two, were assessed as having low risk of bias according to The JBI critical appraisal criteria for case reports [ 20 , [25] , [26] , [27] , [28] , [29] , 31 , 32 , 36 , 37 ]; cohort studies [ 18 ]; cross-sectional studies [ 16 , 17 , [22] , [23] , [24] , 38 , 39 ] and case series [ 19 , 21 , 30 , 34 ]. Two case reports [ 33 , 35 ] were assessed to have a high and moderate risk of bias due to reasons mentioned in Table- 2 .…”

Section: Resultsmentioning

confidence: 99%